Pulmatrix (PULM) vs Soligenix (SNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Soligenix is the larger company by market cap ($5.1 million vs $4.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PULM | SNGX |
|---|---|---|
| Share price | $1.27 | $0.2201 |
| Market cap | $4.64M | $5.14M |
| 1-day change | -10.56% | -8.29% |
| EPS (TTM) | $-1.20 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-5.16M | $-11.08M |
| 52-week high | $4.94 | $1.70 |
| 52-week low | $1.06 | $0.21 |
| Distance from 52-week high | -74.29% | -87.05% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +526.99% |
| Average volume | 35.45K | 198.15K |
| Shares outstanding | 3.65M | 23.37M |
| Employees | 2 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pulmatrix
PULM stock →Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Soligenix
SNGX stock →Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
PULM vs SNGX FAQ
Which is bigger, Pulmatrix or Soligenix?
Soligenix (SNGX) is larger, with a market capitalization of $5.14M compared with $4.64M for Pulmatrix (PULM).
Are Pulmatrix and Soligenix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.